A better way to control where drugs go? Investors bet on small biotech's mission to 'click' together cancer meds
While José Mejía Oneto was an orthopedic surgery resident at UC Davis, he learned an intriguing yet frustrating fact: Only small amounts of a drug — in some cases just 1% or 2% of what’s administered — actually make it to the target location.
That concerning fact left Mejía Oneto with one question, one that would change the trajectory of his entire career — how can we better control where drugs go?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.